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Abstract. Liver cirrhosis complications are difficult to treat by active 
drug delivery, because of drug metabolizing enzymes secreted by liver. 
The difficulties are solved by specific liver targeted drug delivery system. 
We designed liver targeting by galactosylated chitosan nanoparticles 
loaded Silymarin. Targeted delivery of drug to hepatic can be successful-
ly achieved by binding to asialoglycoprotien receptor which is present in 
liver cells. The prepared galactosylated and chitosan nanoparticles were 
evaluated by physiochemical parameters like particles size, morphology, 
entrapment efficiency, zeta potential and in-vitro release studies. The 
successful formulation was subjected to in-vivo evaluation studies like 
organ drug distribution studies and hepatoprotective activity by calcu-
lating SGOT, SGPT concentration. Based on plasma drug concentration 
profile, pharmacokinetics parameters like AUC, AUMC, Cmax, Tmax, t1/2, 
MRT & clearances were evaluated. The above results indicate galacto-
sylated chitosan nanoparticles might be the best suitable carrier to tar-
get liver cells in treating liver cirrhosis. 
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Introduction. Targeted drug delivery is defined as a satisfactory treat-
ment schedule to enhance therapeutic action, minimising any adverse 
drug reaction and can be reached by specific identification processes like 
ligand-receptor, antibody antigen identification and also vehicle 
transport. The target recognition depends on the difference of molecules 
expression between disease associated cells and their normal counter 
parts such as proteases, receptors or adhesion molecules [1]. Some liver 
diseases like hepatitis, hepatic cirrhosis and hepatoma develop in liver 
parenchyma cells. Asialoglycoprotien receptors present only on parenchy-
ma cell surfaces of mammals’ liver which can identify and linked with 
galactose and N- acetyl galactosamine terminated glycoproteins have 
been widely suitable for hepatocytes accurate targeting of drug by recep-
tor mediated endocytosis [2]. The asialoglycoprotein receptors are also 
present in cirrhosis cells after the proceed of receptor-mediated endocy-
tosis (RME) step [3]. Since then, last decade, several scientific concepts 
have been investigated to target sugar-receptor mediated transport sys-
tem to selectively target liver cells. One of the prominent ways is that 
dugs conjugate with sugar ligand directly linked by covalent bond to form 
prodrugs. Some of the sugar molecules like galactose and carbon conju-
gate with protein and polypeptide compounds by covalent bond and then 
they can be identified and targeted in the liver via binding of asialoglyco-
protien receptor. Some of the polymeric materials, like poly-L-Lysine (PLL) 
[4], chitosan [5], poly (L- glutamic hydrazide), and poly-(L-glutamic acid) 
PLGA [2] are used for organ targeting. Galactosylated albumin-
methotrexate shows intensified hepatocytes uptake and liver specificity 
[6]. Cirrhosis is a slowly progressive disease in which healthy liver is re-
placed with fibrous tissue eventually preventing the liver from working 
properly. The fibrous tissue blocks the blood flow through the liver and 
slows down the metabolizing of nutrients, hormones, drugs and naturally 
produced toxins [7]. According to the national institute of health, liver 
cirrhosis is the 12thleading cause of death worldwide. Excess of alcohol, 
non-alcoholic steatohepatitis (NASH), chronic viral hepatitis, fatty liver 
and alcohol abuse are the most common causes of cirrhosis of the liver. 
Primary biliary cirrhosis, autoimmune chronic active hepatitis, drugs and 
chemicals, metabolic and inherited disorder which cause liver fibrosis 
eventually forms irreversible cirrhosis of liver in human. There is no ideal 
treatment for liver cirrhosis. There is a requirement to find ultimate treat-
ment for cirrhosis. The cell regenerative therapy would be one that tar-
gets the liver effectively, prolong the drug release, well tolerated action 
particularly to necrosis tissues in liver [8]. Chitosan is a natural carbohy-
drate polymer prepared from chitin and it has been proposed as ultimate 
biocompatible polymers that are mainly suitable for gene delivery, vac-
cine delivery and mucosal drug delivery. Chemically modified chitosan are 
beneficial in sustained release and targeting studies of all categories of 
drugs. Chitosan are soluble in acetic solution at pH 6.5, whereas primary 
amino group are protonated. To increase the water solubility of chitosan 
it was coupled with lactobionic acid carrier like galactose group as the 
specific ligand to the asialoglycoprotien receptor of liver cells. The binding 
of the galactose ligand with specific receptor induces liver targeted trans-
fer of drug [9]. Silymarin is a naturally occurring flavono lignans which 
comprise of silybin B, Isosilybin A, B, silychristin and silydianin, although it 
is significantly suitable for the treatment of liver cirrhosis [10]. The drug 
achieved less satisfaction because of high metabolic enzyme concentra-
tion in liver, poor solubility, low bioavailability and low half life. Thus, 
targeting delivery of Silymarin to hepatic cell may be an effective technol-
ogy for the treatment of liver cirrhosis. In the current research, galacto-
sylated chitosan loaded Silymarin nanoparticles were synthesized, and 
their physiochemical properties, drug release characters and target speci-
ficity was analysed. 
 
Material and methods. Silymarin was kindly supplied by Grandix pharma-
ceuticals, India. Chitosan and galactose was purchased from Vikaash 
Chemicals, India.N-hydroxyl succinamide (NHS) and N, N’ dicyclo hexyl 
carbidimide (NNDCHC) was purchased from Sigma Aldrich, India. All other 
reagents used in research were of analytical grade. Synthesis of galacto-
sylated chitosan nanoparticles. Galactose solution (galactose in acetate 
buffer) was activated with a mixture of N-hydroxyl succinamide (NHS) and 
N, N’ dicyclo hexyl carbidimide (NNDCHC) (Figure 1). Subsequently, chi-
tosan solution (chitosan dissolved in 2 % of aqueous glacial acetic acid) 
was added into the solution at equivalent molar ratio of galactose. The 
reaction was performed at 25ºC for 72 h with continuous stirring [11] to 
form galactosylated chitosan. Finally silymarin was added and stirred 
continuously for further 6 h by addition of 2% glutraldehyde as across 
linking agent. The formed nanoparticles suspension was centrifuged at 
15000rpm for 30 minutes and the precipitate was freeze dried at -20ºC 
under reduced pressure. The prepared nanoparticles were used for fur-
ther evaluation studies. Characterization of nanoparticles. Morphology, 
particle size & zeta potential. Morphology of silymarin loaded galactosyl-
ated chitosan and silymarin loaded chitosan nanoparticles were snapped 
by scanning electron microscopy (SEM). Particle size was measured by 
using zeta sizer 3000 HS (Malvern instruments, UK). Samples were diluted 
with distilled water and measured at 25ºC. The diameter was calculated 
from autocorrelation function of the intensity of light scatter and zeta 
potential was measured by placement in electrophoretic cell at 150mV 
potential. Entrapment efficiency (EE %). Entrapment efficiency was calcu-
lated by measuring the quantity of the entrapped drug. This was found by 
measuring the absorbance of the drug in supernant liquid, which was 
obtained after ultracentrifugation of nanoparticles suspension (12). The 
EE was calculated by using the following formula : 
 
Where, W1 is weight of entrapped drugs, W2 is the total weight of drugs 
used. In-vitro release study. In-vitro release study of galactosylated nano-
particles was carried out by using modified Franz diffusion apparatus at 
37+ 2 ºC. About50mg drug equivalent nanoparticles were suspended in 
donor compartment containing phosphate buffer (pH 7.4). Drug release 
was assessed by intermittently sampling the receptor medium (5mL) and 
fresh phosphate buffer saline pH 7.4 was replaced [13]. The samples were 
filtered with membrane filter (0.22μ) and the amount of drug released 
was quantified by a U.V spectrophotometer at 252nm. In-vivo Evaluation 
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Studies. Preparation of Animal for Studies. For organ drug distribution 
studies, 4-6 weeks old Wister rats weighing 200-260 g were obtained 
from institutional animal house (AIMST Univeristy, Malaysia). The animals 
were maintained at standard laboratory conditions with diet and provid-
ed tap water ad libitum. Organ Drug Distribution Studies. Nine wister 
rats were kept on a lighting standard 12h on/12h off cycle and they were 
fasted for 12h. The animals were divided into three groups; each group 
consisted of 3 rats. Group I-sterile phosphate buffer saline solution, group 
II- pure silymarin solution intravenous injection (30 mg/kg) and group III& 
IV - chitosan silymarin nanoparticle and galactosylated chitosan silymarin 
nanoparticle containing the equivalent of 30 mg/kg solution intravenously 
by tail vein after redispersed in sterile phosphate buffer saline solution. 
After 40 h, the rats were sacrificed and their liver, lungs and kidney were 
separated. The organs were washed thoroughly in sterile phosphate buff-
er saline solution to remove adhering debris and coagulated blood. The 
liver, lungs and kidney were separated and kept in refrigerated. It was 
cross chopped with surgical scalpel into fine slices and chilled in the cold 
0.25 M sucrose solution (85.87 g of sucrose was dissolved in 1000 mL of 
distilled water), quickly blotted with filter paper. The tissue was minced 
and homogenized in ice cold 10 mMTris buffer (1.2 g of Tris was dissolved 
in 900 mL of distilled water; pH was adjusted to 7.4 with 1M HCl and 
diluted up to 1000 mL) at a concentration of 10% w/v by using homoge-
nizer at a speed of 2500 rpm. The prolonged homogenization under hypo-
tonic condition was designed to disrupt as far as possible the ventricular 
structure of cells, so as to release soluble protein and leave only mem-
brane and non vascular matter in sediment form. It was centrifuged in 
cooling centrifuge at 5000 rpm for 20 min at -4°C.  The clear supernatant 
was separated and used to estimate drug content. Evaluation of hepato-
protective activity. Hepatoprotective activity of silymarin nanoparticles 
were evaluated by carbon tetrachloride (CCl4)-induced liver damage mod-
el [14].  For this purpose a separate set of Wister rats were divided into 
five groups each containing 5 rats. Group1 received normal saline (1 mL) 
daily for 7 days and served as control. Group 2 received CCl4 (dissolved in 
3 times its volume of olive oil) at a dose of 0.7 mL/kg intraperitoneally on 
days 2, 4and 7 and served as toxic control. Group 3 received the silymarin 
solution in a dose of 30 mg/kg intravenously daily for 7 days. Group 4 
received chitosan silybin nanoparticle suspension equivalent to 30 mg/kg 
of drug intravenously on day 1.Group 5 received galactosylated chitosan 
silymarin nanoparticle suspension equivalent to 30 mg/kg of drug intrave-
nously on day 1. All the groups received CCl4at 1, 3, 5 and 7days of the 
study except normal control. The animals were anaesthetized on the last 
day of the study and blood was collected by cardiac puncture. Plasma was 
separated from the blood samples by centrifugation at 5000 rpm for 15 
min. Hepatoprotective activity was quantified by serum glutamate oxalo-
acetate transaminase (SGOT) and serum glutamate pyruvic transaminase 
(SGPT) levels in the plasma. Finally pharmacokinetic parameters like AUC, 
AUMC, Cmax, Tmax, t1/2, MRT& clearances were also evaluated by using PK 
Solver Version 4.0 software. At the same time, their livers were subjected 
to histopathological examination. First, the rats were sacrificed at the last 
day of the study, the liver separated carefully and preserved in formalin 
solution, and liver sections were prepared. [14]. Statistical Analysis. Parti-
cle size, entrapment efficiency& zeta potential data were compared using 
student t’s test and in-vivo data was analysed by one-way ANOVA and the 
turkey test. Differences were considered significant when p < 0.05. 
 
Result and Discussion. The preparation of chitosan and galactosylated 
chitosan nanoparticles is represented in fig.1. Galactosylated chitosan 
was prepared by condensation of chitosan and lactobionic acid presence 
of mixture of N-hydroxyl succinamide (NHS) and N, N’ dicyclo hexyl car-
bidamide. The lactobionic acid contains galactose functions group can 
have specific targeting of asialoglycoprotien receptors present in hepatic 
cells [15]. In the galactosylated chitosan the silymarin was entrapped by 
the addition of glutraldehyde as a cross linking agents. The synthesized 
nanoparticles were freeze dried in order to get powder form. The synthe-
sis of galactosylated chitosan and ungalactosylated chitosan were used 
for silymarin leaded nanoparticles preparations. The particle size of pre-
pared nanoparticles were analysed by scanning electron microscope 
(SEM). The particle size of chitosan and galactosylated chitosan nanopar-
ticles were 110 & 123 nm respectively (Table 1). Particle size of nanoparti-
cle play a key role in the transport of drugs to the receptor level and the 
size of less than 200nm is best suited for increasing the cellular uptake of 
nanoparticle. Galactosylated chitosan nanoparticles size was higher than 
the chitosan nanoparticle, which could be due to replacing amino group 
of chitosan by lactobionic acid Nanoparticle morphology was observed by 
scanning electron microscopy (SEM). All the nanoparticles appeared 
spherical in shape (Figure 2). Zeta potential of chitosan and galactosylated 
chitosan nanoparticles were +33.20mV & +28.52mV respectively (Table 
1). The zeta potential of galactosylated chitosan nanoparticle was re-
duced due to conjugation of negative charge of silymarin. Entrapment 
efficiency is the important parameter to optimize the nanoparticle formu-
lations. In the silymarin nanoparticle preparation, chitosan nanoparticle 
showed 58.12% and 70.24 % of galactosylated nanoparticle (Table 1). 
Galactosylated chitosan nanoparticle was higher than chitosan nanoparti-
cle, due to over coating of galactose (increased polymer concentration). 
The entrapment efficiency was attained by addition of cross linking agent 
in the nanoparticle preparations. In-vitro drug release data shown in fig-
ure 3 indicated that, both nanoparticle preparations showed sustained 
release over a period of 48 h. The nanoparticles released Silymarin by 
biphasic pattern; an initial burst followed by continuous slow release. 
Initially both the formulations show 8.62 & 11.44% at 2 h, due to unen-
trapped drug molecules which is present at surface of nanoparticles. 
Subsequently, the entrapped drug was released gradually. The galactosyl-
ated chitosan nanoparticle shows higher drug release compared with 
chitosan nanoparticle. In the drug release slight variations shows, may be 
of cross link of galactose with chitosan. The nanoparticle formulations 
were evaluated by organ distribution studies by scarifying rats. The liver, 
brain, lungs & kidney were isolated and content was analyzed. A larger 
quantity of silymarin was accumulated in liver 31.4±1.6µg/ g of tissues & 
58.1±1.2µg/ g of tissues of organ for chitosan nanoparticles and galacto-
sylated chitosan nanoparticles respectively (Figure 4).Silymarin loaded 
galactosylated Chitosan nanoparticle was targeted the asioglycon recep-
tor of liver cells and distributing the silymarin by bonding. So the galacto-
sylated nanoparticles showed elevated drug distribution compared to 
other organ in the body. Hepatoprotective activity data was showed in 












































Figure 1. Synthesis of galatosylated chitosan. 
Formulations  Particle size  
(nm)  
EE (%)  Zeta potentia(mV)  
CSO/SLY nanoparticle  110±1.10  58.12±0.4  +33.20±2.30  
Gal-CSO/SLY nanoparticle  123±2.22  70.24±0.6  +28.52±1.45  
Table 1. Physiochemical parameters of Silymarin loaded nanoparticle formulations. Mean± SD, n=3. Where EE= Entrapment efficiency.
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table 2. Carbon tetrachloride (CCl4) administered animals showed marked 
increases in the hepatic enzymes like SGPT & SGOT, which induces the 
hepatic toxicity. The CCl4 induces the liver damage by releasing metabo-
lite (CCl3), which binds to lipoprotein present in liver cells. It induces the 
peroxidation of the lipids of the endoplasmic reticulum by the action of 
cytochrome P450 oxygenase system. The free radicals react rapidly with 
oxygen to form highly reactive trichloro methyl peroxy radical (CCl3COO). 
Both radicals were drastically damaging the liver cells. After administra-
tion of silymarin and its nanoparticles formulations were showed marked 
reduced elevated enzymes level in blood. Galactosylated chitosan loaded 
silymarin nanoparticle showed 11.4 & 35.4 U/L of SGPT and SGOT respec-
tively as compared to chitosan loaded silymarin nanoparticles (Table 2). 
The rapid changes were observed due to ultimate targeting of galactosyl-
ated nanoparticles to asioglycon protein of liver cells. Both nanosized 
formulations showed marked uptake by liver cells. Receptor reorganiza-
tion was observed only in galactosylated chitosan nanoparticles com-
pared to chitosan nanoparticle. Histopathological images of figure 5 
shows changes in liver cells by various administrations of silymarin nano-
particles formulations. In the control normal animals showed good he-
patic cells framework, proper arrangement of cytoplasm sinusoidal spac-
es with perfect central vein. However, there was disarrangement of nor-
mal liver cells with extreme centrilobular necrosis in CCl4 administered 
rats liver cells. Average arrangement of fatty lobules and cellular necrosis 
were shown in silymarin solution (IV) treated animals. Whereas Gal-CSO/
SLY and CSO/SLY treated animals showed normal hepatic cords, well 
arranged cytoplasm, central vein and absences of necrosis cells. This 
report evidenced that, nanoparticle formulations exhibited strong protec-
tion against CCl4- induced liver damage. Based on plasma concentration 












































Figure 2. A) SEM image of CSO/SLY nanoparticles. B) SEM image of Gal-CSO/SLY nanoparticles.            
A B 
Figure 3. In-vitro drug release studies of nanoparticle formulations. All 
the values are mean of three invitro drug release experiment. *P≥0.05 
compare with CSO/SLY nanoparticle (Two way ANOVA with Bonferroni 
post-hoc test). 
Figure 4. Organ drug distribution studies. 
Groups SGPT (U/L) SGOT(U/L) 
Body weight (gm) 
Initial After 7 days 
I. Control 10.2±1.6 31.2±2.1 210±8 220±15 
II. Negative 72.5±2.4 90.6±3.6 210±10 190±5 
III. Silymarin solution(IV) 42.2±2.0* 64.1±3.1* 220±6* 225±6* 
IV. CSO-SLY nanoparticle 18.6±3.1** 41.6±4.2** 215±15** 225±10** 
V. Gal-CSO/SLY nanoparticle 11.4±2.6** 35.4±2.0** 210±10** 230±6** 
Table 2. Hepatoprotective activity of Silymarin loaded nanoparticle formulations. Mean ± SD, n=5. SGPT-Serum Glutamate Pyruvic Transaminase, 
SGOT- Serum Glutamate Oxaloacetate Transaminase.  Where **p≤0.01, * p≤0.05 compared with CCl4. 
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time profile (Figure 6), pharmacokinetic parameters were calculated by 
using PK solver software. The pharmacokinetics parameters Cmax, Tmax, 
AUC, AUMC, MRT, t1/2 and clearances of silymarin solution (IV) were 5.2 
µg/mL, 2h, 5.2 h, 58.43 μg/mL*h, 532.2 μg/mL*h^2, 8.6h & 1.6 μg/mL)/h 
respectively. In case of CSO-SLY nanoparticles formulation showed 4.6 
µg/mL, 24h, 36.5 h, 203.2 μg/mL*h, 11426.4 μg/mL*h^2, 51.18h & 3.7 
μg/mL)/h respectively. Whereas Gal-CSO/SLY nanoparticle formulation 
showed 6 µg/mL, 48h, 32.8 h, 431.04 μg/mL*h, 29172.3 μg/mL*h^2, 
64.15h & 1.8 μg/mL)/h respectively (Table 3). The significant increased 
Cmax, Tmax, AUC, AUMC, MRT of galatosylated chitosan nanoparticles 
clearly demonstrate the prolong circulation properties of nanoparticles. 
The less clearance and high t1/2 values indicate the sustained release of 
galactosylated chitosan nanoparticle. These pharmacokinetics values 
indicated that, silymarin concentration was significantly maintained 
throughout the time upto 7 days. The relative bioavailability of Gal-CSO/
SLY nanoparticle formulation was high when compared with CSO-SLY 
nanoparticle formulation. The good bioavailability was maintained by 
specific targeting action of Gal-SCO/SLY nanoparticle. The uptake of Gal-
SCO/SLY and CSO-SLY nanoparticles haven’t shown any cytotoxicity 
effects on animals. 
 
Conclusion. In the present study, we synthesis galactosylated chitosan 
and has the strength to form nanoparticles when loaded with silymarin. 
The prepared nanoparticles showed optimized physiochemical properties 
for delivery of silymarin to target liver cells. The targeting efficiency was 
confirmed by organ drug distribution studies. The galactosylated chitosan 
have more hepatoprotective activity compared to chitosan nanoparticle 
due to the specific binding of asialoglycoprotein receptor. Both nanopar-
ticles are having good release properties, but targeting efficiency was 
better in Gal-CSO/SLY than CSO/SLY nanoparticles. Furthermore pharma-
cokinetic parameters showed evidence to confirm that galactosylated 
chitosan nanoparticle might be the best carrier for targeting liver cells. 
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SLY nanoparticle treated liver cells. 
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